(BAYN) Bayer NA - Ratings and Ratios
Pharmaceuticals, Consumer Health, Crop Science, Medicines, Seeds
BAYN EPS (Earnings per Share)
BAYN Revenue
Description: BAYN Bayer NA
Bayer AG operates as a global life science company, divided into three main segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment focuses on cardiology, womens health, oncology, and other specialty therapeutics, while Consumer Health provides over-the-counter medicines and nutritional supplements. Crop Science offers crop protection products, seeds, and digital solutions for agriculture.
From a financial perspective, Bayers market capitalization stands at approximately €26.85 billion. The companys forward Price-to-Earnings ratio is 5.98, indicating a relatively low valuation compared to its expected earnings. However, the Return on Equity (RoE) is negative at -9.96%, suggesting that the company has faced challenges in generating profits for shareholders in the recent past.
To further analyze Bayers performance, key performance indicators (KPIs) such as Revenue Growth, EBITDA Margin, and Debt-to-Equity ratio can be considered. Bayers revenue growth has been impacted by various factors, including litigation and settlement costs related to glyphosate-based products. The EBITDA margin, which measures the companys profitability, has also been affected by these challenges. Additionally, Bayers Debt-to-Equity ratio is relatively high, indicating a significant level of indebtedness.
From a valuation perspective, Bayers stock price has shown a positive trend, with the 20-day Simple Moving Average (SMA) at €26.78 and the 50-day SMA at €25.85, both above the 200-day SMA of €23.12. The Average True Range (ATR) is 0.53, equivalent to 1.89% of the current price, indicating moderate volatility. The stocks 52-week high and low are €30.30 and €18.78, respectively.
BAYN Stock Overview
| Market Cap in USD | 32,336m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception |
BAYN Stock Ratings
| Growth Rating | -21.0% |
| Fundamental | 50.4% |
| Dividend Rating | 0.41% |
| Return 12m vs S&P 500 | -13.0% |
| Analyst Rating | - |
BAYN Dividends
| Dividend Yield 12m | 0.43% |
| Yield on Cost 5y | 0.22% |
| Annual Growth 5y | -47.66% |
| Payout Consistency | 85.9% |
| Payout Ratio | 2.2% |
BAYN Growth Ratios
| Growth Correlation 3m | 53.1% |
| Growth Correlation 12m | 40% |
| Growth Correlation 5y | -60.1% |
| CAGR 5y | -15.46% |
| CAGR/Max DD 3y | -0.23 |
| CAGR/Mean DD 3y | -0.30 |
| Sharpe Ratio 12m | 1.15 |
| Alpha | -3.68 |
| Beta | 0.178 |
| Volatility | 31.14% |
| Current Volume | 2369.1k |
| Average Volume 20d | 1866.6k |
| Stop Loss | 26.5 (-3.6%) |
| Signal | -1.32 |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (-3.42b TTM) > 0 and > 6% of Revenue (6% = 2.77b TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.60% (prev 18.22%; Δ -9.62pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 7.15b > Net Income -3.42b (YES >=105%, WARN >=100%) |
| Net Debt (-4.56b) to EBITDA (6.55b) ratio: -0.70 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.13 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (982.4m) change vs 12m ago 0.0% (target <= -2.0% for YES) |
| Gross Margin 54.95% (prev 58.07%; Δ -3.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.03% (prev 39.31%; Δ 1.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.83 (EBITDA TTM 6.55b / Interest Expense TTM 1.71b) >= 6 (WARN >= 3) |
Altman Z'' 0.69
| (A) 0.04 = (Total Current Assets 33.75b - Total Current Liabilities 29.78b) / Total Assets 105.24b |
| (B) 0.11 = Retained Earnings (Balance) 11.67b / Total Assets 105.24b |
| (C) -0.01 = EBIT TTM -1.42b / Avg Total Assets 112.55b |
| (D) 0.16 = Book Value of Equity 12.11b / Total Liabilities 74.74b |
| Total Rating: 0.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 50.39
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield 6.23% = 3.11 |
| 3. FCF Margin 9.95% = 2.49 |
| 4. Debt/Equity 1.70 = 1.20 |
| 5. Debt/Ebitda 7.89 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -10.91% = -1.82 |
| 8. Rev. Trend -9.63% = -0.48 |
| 9. Rev. CAGR -1.77% = -0.30 |
| 10. EPS Trend -12.72% = -0.32 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BAYN shares?
Over the past week, the price has changed by -2.65%, over one month by +1.68%, over three months by -0.27% and over the past year by +3.45%.
Is Bayer NA a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BAYN is around 23.31 EUR . This means that BAYN is currently overvalued and has a potential downside of -15.24%.
Is BAYN a buy, sell or hold?
What are the forecasts/targets for the BAYN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28.5 | 3.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 25.6 | -7% |
BAYN Fundamental Data Overview
Market Cap EUR = 27.58b (27.58b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 5.50b EUR (Cash And Short Term Investments, last quarter)
P/E Forward = 5.5188
P/S = 0.5972
P/B = 0.9326
P/EG = 4.716
Beta = 1.002
Revenue TTM = 46.17b EUR
EBIT TTM = -1.42b EUR
EBITDA TTM = 6.55b EUR
Long Term Debt = 44.95b EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 6.72b EUR (from shortTermDebt, last quarter)
Debt = 51.67b EUR (Calculated: Short Term 6.72b + Long Term 44.95b)
Net Debt = -4.56b EUR (from netDebt column, last quarter)
Enterprise Value = 73.76b EUR (27.58b + Debt 51.67b - CCE 5.50b)
Interest Coverage Ratio = -0.83 (Ebit TTM -1.42b / Interest Expense TTM 1.71b)
FCF Yield = 6.23% (FCF TTM 4.59b / Enterprise Value 73.76b)
FCF Margin = 9.95% (FCF TTM 4.59b / Revenue TTM 46.17b)
Net Margin = -7.40% (Net Income TTM -3.42b / Revenue TTM 46.17b)
Gross Margin = 54.95% ((Revenue TTM 46.17b - Cost of Revenue TTM 20.80b) / Revenue TTM)
Tobins Q-Ratio = 6.09 (Enterprise Value 73.76b / Book Value Of Equity 12.11b)
Interest Expense / Debt = 0.96% (Interest Expense 495.0m / Debt 51.67b)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 1.13 (Total Current Assets 33.75b / Total Current Liabilities 29.78b)
Debt / Equity = 1.70 (Debt 51.67b / last Quarter total Stockholder Equity 30.37b)
Debt / EBITDA = 7.89 (Net Debt -4.56b / EBITDA 6.55b)
Debt / FCF = 11.25 (Debt 51.67b / FCF TTM 4.59b)
Total Stockholder Equity = 31.32b (last 4 quarters mean)
RoA = -3.25% (Net Income -3.42b, Total Assets 105.24b )
RoE = -10.91% (Net Income TTM -3.42b / Total Stockholder Equity 31.32b)
RoCE = -1.87% (Ebit -1.42b / (Equity 31.32b + L.T.Debt 44.95b))
RoIC = unknown (NOPAT none, Invested Capital 41.18b, Ebit -1.42b)
WACC = unknown (E(27.58b)/V(79.25b) * Re(6.67%)) + (D(51.67b)/V(79.25b) * Rd(0.96%) * (1-Tc(none)))
Shares Correlation 3-Years: -27.52 | Cagr: 0.0%
Discount Rate = 6.67% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 73.73% ; FCFE base≈4.68b ; Y1≈3.58b ; Y5≈2.23b
Fair Price DCF = 42.60 (DCF Value 41.85b / Shares Outstanding 982.4m; 5y FCF grow -27.83% → 3.0% )
Revenue Correlation: -9.63 | Revenue CAGR: -1.77%
Rev Growth-of-Growth: 2.14
EPS Correlation: -12.72 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -44.53